Nagi <span>B.</span> Kumar
Researcher

Nagi B. Kumar

Academic Rank: Senior Member

Overview

Discipline

    • Cancer Epidemiology
    • Genitourinary Oncology
    • Cancer Chemoprevention Research Interest Group
    • Cancer Epidemiology Program

Education & Training

    • University of South Florida, Tampa, Florida, MA - Adult Education
    • University of South Florida, Tampa, Florida, PhD - Interdisciplinary Studies, Applied Behavior Analysis & Public Health Nutrition
Research

Dr. Nagi Kumar’s research focusses on systematically identifying and evaluating agents, mechanisms and biomarkers targeting high risk populations for cancer chemoprevention, treatment and management of late effects of cancer treatment.

Publications

  • Handing EP, Small BJ, Andel R, McEvoy CL, Kumar N. Can Nutrition or Inflammation Moderate the Age-Cognition Association Among Older Adults?. J Gerontol B Psychol Sci Soc Sci. 2017 May. Pubmedid: 28482093.
  • Leone A, Diorio G, Sexton W, Schell M, Alexandrow M, Fahey JW, Kumar NB. Sulforaphane for the chemoprevention of bladder cancer: molecular mechanism targeted approach. Oncotarget. 2017 May;8(21):35412-35424. Pubmedid: 28423681. Pmcid: PMC5471065.
  • Luu HN, Lin HY, Sørensen KD, Ogunwobi OO, Kumar N, Chornokur G, Phelan C, Jones D, Kidd L, Batra J, Yamoah K, Berglund A, Rounbehler RJ, Yang M, Lee SH, Kang N, Kim SJ, Park JY, Di Pietro G. miRNAs associated with prostate cancer risk and progression. BMC Urol. 2017 Mar;17(1):18. Pubmedid: 28320379. Pmcid: PMC5359825.
  • Kumar NB, Patel R, Pow-Sang J, Spiess PE, Salup R, Williams CR, Schell MJ. Long-term supplementation of decaffeinated green tea extract does not modify body weight or abdominal obesity in a randomized trial of men at high risk for prostate cancer. Oncotarget. 2017 Jun. Pubmedid: 28678746.
  • Kumar NB, Pow-Sang J, Spiess PE, Park J, Salup R, Williams CR, Parnes H, Schell MJ. Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins. Oncotarget. 2016 Oct;7(43):70794-70802. Pubmedid: 28053292. Pmcid: PMC5340117.
  • Kumar NB, Pow-Sang JM, Spiess PE, Park JY, Chornokur G, Leone AR, Phelan CM. Chemoprevention in African American Men With Prostate Cancer. Cancer Control. 2016 Oct;23(4):415-423. Pubmedid: 27842331.
  • Kumar NB, Pow-Sang J, Egan KM, Spiess PE, Dickinson S, Salup R, Helal M, McLarty JW, Williams CR, Schreiber F, Parnes HL, Sebti S, Kazi A, Kang L, Quinn GP, Smith T, Yue B, Diaz K, Chornokur G, Crocker T, Schell MJ. Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention. Cancer Prev Res (Phila). 2015 Oct;8(10):879-887. Pubmedid: 25873370. Pmcid: PMC4596745.
  • Mohammad RM, Muqbil I, Lowe L, Yedjou C, Hsu HY, Lin LT, Siegelin MD, Fimognari C, Kumar NB, Dou QP, Yang H, Samadi AK, Russo GL, Spagnuolo C, Ray SK, Chakrabarti M, Morre JD, Coley HM, Honoki K, Fujii H, Georgakilas AG, Amedei A, Niccolai E, Amin A, Ashraf SS, Helferich WG, Yang X, Boosani CS, Guha G, Bhakta D, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Keith WN, Bilsland A, Halicka D, Nowsheen S, Azmi AS. Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol. 2015 Dec;35 Suppl:S78-103. Pubmedid: 25936818. Pmcid: PMC4720504.
  • Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin AR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AM, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Feitelson MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Niccolai E, Nowsheen S, Panis C, Pantano F, Parslow VR, Pawelec G, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, Rathmell WK, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, ...
  • Kumar NB, Quinn GP, Alexandrow MG, Gray J, Schell M, Sutton S, Haura EB. Chemoprevention Trial Feasibility Using Botanicals in Exceptionally High Risk Populations for Lung Cancer. J Clin Trials. 2014 Sep;4(4). Pubmedid: 26101725. Pmcid: PMC4474484.
  • Chornokur G, Amankwah EK, Davis SN, Phelan CM, Park JY, Pow-Sang J, Kumar NB. Variation in HNF1B and Obesity May Influence Prostate Cancer Risk in African American Men: A Pilot Study. Prostate Cancer. 2014 Jan;2013:384594. Pubmedid: 24386569. Pmcid: PMC3872424.
  • Kim S, Amankwah EK, Connors S, Park HY, Rincon M, Cornnell HH, Chornokur G, Ibrahim-Hashim A, Choi J, Tsai YY, Engelman R, Kumar NB, Park JY. Safety and chemopreventive effect of Polyphenon E in preventing early and metastatic progression of prostate cancer in TRAMP mice. Cancer Prev Res (Phila). 2014 Apr;7(4):435-444. Pubmedid: 24501325. Pmcid: PMC4123218.
  • Green BL, Rivers DA, Kumar N, Baldwin J, Rivers BM, Sultan D, Jacobsen P, Gordon LE, Davis J, Roetzheim R. Establishing the infrastructure to comprehensively address cancer disparities: a model for transdisciplinary approaches. J Health Care Poor Underserved. 2013 Nov;24(4):1614-1623. Pubmedid: 24185157. Pmcid: PMC4163783.
  • Deng GE, Rausch SM, Jones LW, Gulati A, Kumar NB, Greenlee H, Pietanza MC, Cassileth BR. Complementary therapies and integrative medicine in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl):e420S-e436S. Pubmedid: 23649450.
  • Kumar NB, Dhurandhar M, Aggarwal B, Anant S, Daniel K, Deng G, Djeu J, Dou J, Hawk E, Jayaram B, Jia L, Joshi R, Kararala M, Karunagaran D, Kucuk O, Kumar L, Malafa M, Samathanam GJ, Sarkar F, Siddiqi M, Singh RP, Srivastava A, White JD. Proceedings of the Indo-U.S. bilateral workshop on accelerating botanicals/biologics agent development research for cancer chemoprevention, treatment, and survival. Cancer Med. 2013 Feb;2(1):108-115. Pubmedid: 24279005. Pmcid: PMC3797562.
  • Chornokur G, Kumar NB. Prostate cancer chemoprevention in men of African descent: current state of the art and opportunities for future research. Cancer Causes Control. 2013 Aug;24(8):1465-1480. Pubmedid: 23737026. Pmcid: PMC4184029.
  • Alexandrow MG, Song LJ, Altiok S, Gray J, Haura EB, Kumar NB. Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer. Eur J Cancer Prev. 2012 Sep;21(5):407-412. Pubmedid: 22156994. Pmcid: PMC3319490.
  • Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Slaton J, Anderson JK. Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer. Contemp Clin Trials. 2012 Mar;33(2):279-285. Pubmedid: 22101219. Pmcid: PMC3268882.
  • Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Connors S, Chornukur G, Dickinson SI, Bai W, Williams CR, Salup R, Fu W. Prostate Cancer Chemoprevention Targeting High Risk Populations: Model for Trial Design and Outcome Measures. J Cancer Sci Ther. 2012 Mar;2011(S3). Pubmedid: 22422102. Pmcid: PMC3300067.
  • Kumar NB, Vadaparampil ST, Mahajan N, Lilienfeld HS, Lee JH, Laronga C, Hakam A, Hein JJ, Egan KM, Arun B, Pal T. Metformin- A Promising Agent for Chemoprevention in BRCA1 Carriers. Hereditary Genet. 2012 Jun;1(2). Pubmedid: 26097796. Pmcid: PMC4474476.
  • Connors SK, Chornokur G, Kumar NB. New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer. Nutr Cancer. 2012 Jul;64(1):4-22. Pubmedid: 22098273. Pmcid: PMC3665011.
  • Kumar N, Crocker T, Smith T, Connors S, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Anderson K. Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures. J Clin Trials. 2012 Jan;2(1). Pubmedid: 24533253. Pmcid: PMC3924733.
  • Kumar N, Chornokur G. Molecular Targeted Therapies Using Botanicals for Prostate Cancer Chemoprevention. Transl Med (Sunnyvale). 2012 Dec;Suppl 2:005. Pubmedid: 24527269. Pmcid: PMC3920581.
  • Ribeiro MdLC, Silva AS, Bailey KM, Kumar NB, Sellers TA, Gatenby RA, Arig IH, Gillies RJ. Buffer Therapy for Cancer. J Nutr Food Sci. 2012 Aug;2:6. Pubmedid: 24371544. Pmcid: PMC3872072.
  • Chornokur G, Dalton K, Borysova ME, Kumar NB. Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate. 2011 Jun;71(9):985-997. Pubmedid: 21541975. Pmcid: PMC3083484.
  • Brem S, Kumar NB. Management of treatment-related symptoms in patients with breast cancer. Clin J Oncol Nurs. 2011 Feb;15(1):63-71. Pubmedid: 21278042.
  • Kumar NB, Kang L, Pow-Sang J, Xu P, Allen K, Riccardi D, Besterman-Dahan K, Krischer JP. Results of a randomized phase I dose-finding trial of several doses of isoflavones in men with localized prostate cancer: administration prior to radical prostatectomy. J Soc Integr Oncol. 2010 Mar;8(1):3-13. Pubmedid: 20205984. Pmcid: PMC3277948.
  • Kumar NB, Kazi A, Smith T, Crocker T, Yu D, Reich RR, Reddy K, Hastings S, Exterman M, Balducci L, Dalton K, Bepler G. Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. CURR TREAT OPTION ON. 2010 Dec;11(3-4):107-117. Pubmedid: 21128029. Pmcid: PMC3016925.
  • Kumar NB, Yu D, Akinremi TO, Odedina FT. Comparing dietary and other lifestyle factors among immigrant Nigerian men living in the US and indigenous men from Nigeria: potential implications for prostate cancer risk reduction. J Immigr Minor Health. 2009 Oct;11(5):391-399. Pubmedid: 19225888.
  • Kumar N, Titus-Ernstoff L, Newcomb PA, Trentham-Dietz A, Anic G, Egan KM. Tea consumption and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):341-345. Pubmedid: 19124518. Pmcid: PMC3156033.
  • Reams RR, Agrawal D, Davis MB, Yoder S, Odedina FT, Kumar N, Higginbotham JM, Akinremi T, Suther S, Soliman KF. Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study. Infect Agent Cancer. 2009 Feb;4 Suppl 1:S3. Pubmedid: 19208208. Pmcid: PMC2638462.
  • Odedina FT, Akinremi TO, Chinegwundoh F, Roberts R, Yu D, Reams RR, Freedman ML, Rivers B, Green BL, Kumar N. Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. Infect Agent Cancer. 2009 Feb;4 Suppl 1:S2. Pubmedid: 19208207. Pmcid: PMC2638461.
  • Odedina FT, Yu D, Akinremi TO, Reams RR, Freedman ML, Kumar N. Prostate cancer cognitive-behavioral factors in a West African population. J Immigr Minor Health. 2009 Aug;11(4):258-267. Pubmedid: 19051034.
  • Deng GE, Frenkel M, Cohen L, Cassileth BR, Abrams DI, Capodice JL, Courneya KS, Dryden T, Hanser S, Kumar N, Labriola D, Wardell DW, Sagar S. Evidence-based clinical practice guidelines for integrative oncology: complementary therapies and botanicals. J Soc Integr Oncol. 2009 Aug;7(3):85-120. Pubmedid: 19706235.
  • Sellers TA, Vierkant RA, Djeu J, Celis E, Wang AH, Kumar N, Cerhan JR. Unpasteurized milk consumption and subsequent risk of cancer. Cancer Causes Control. 2008 Oct;19(8):805-811. Pubmedid: 18344007. Pmcid: PMC2575230.
  • Kumar NB, Besterman-Dahan K, Kang L, Pow-Sang J, Xu P, Allen K, Riccardi D, Krischer JP. Results of a Randomized Clinical Trial of the Action of Several Doses of Lycopene in Localized Prostate Cancer: Administration Prior to Radical Prostatectomy. Clin Med Urol. 2008 Apr;1:1-14. Pubmedid: 20354574. Pmcid: PMC2846655.
  • Dahan K, Fennal M, Kumar NB. Lycopene in the prevention of prostate cancer. J Soc Integr Oncol. 2008;6(1):29-36. Pubmedid: 18302908.
  • Cassileth BR, Deng GE, Gomez JE, Johnstone PA, Kumar N, Vickers AJ. Complementary therapies and integrative oncology in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007 Sep;132(3 Suppl):340S-354S. Pubmedid: 17873179.
  • Kumar N, Shibata D, Helm J, Coppola D, Malafa M. Green tea polyphenols in the prevention of colon cancer. Front Biosci (Landmark Ed). 2007 Aug;12:2309-2315. Pubmedid: 17127241.
  • Kumar NB, Krischer JP, Allen K, Riccardi D, Besterman-Dahan K, Salup R, Kang L, Xu P, Pow-Sang J. A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer. Nutr Cancer. 2007;59(2):163-168. Pubmedid: 18001210. Pmcid: PMC2435485.
  • Harvie M, Howell A, Vierkant RA, Kumar N, Cerhan JR, Kelemen LE, Folsom AR, Sellers TA. Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):656-661. Pubmedid: 15767346.
  • Kumar N, Allen K, Bell H. Perioperative herbal supplement use in cancer patients: potential implications and recommendations for presurgical screening. Cancer Control. 2005 Jul;12(3):149-157. Pubmedid: 16062162.
  • Kumar N, Riccardi D, Cantor A, Dalton K, Allen K. A case-control study evaluating the association of purposeful physical activity, body fat distribution, and steroid hormones on premenopausal breast cancer risk. Breast J. 2005 Aug;11(4):266-272. Pubmedid: 15982394.
  • Kumar N, Allen K, Riccardi D, Kazi A, Heine J. Isoflavones in breast cancer chemoprevention: where do we go from here?. Front Biosci (Landmark Ed). 2004 Sep;9:2927-2934. Pubmedid: 15353326.
  • Kumar N, Cantor A, Allen K, Riccardi D, Besterman-Dahan K, Seigne J, Helal M, Salup R, Pow-Sang J. The specific role of isoflavones in reducing prostate cancer risk. Prostate. 2004 May;59(2):141-147. Pubmedid: 15042614.
  • Moyers SB, Kumar NB. Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials. Nutr Rev. 2004 May;62(5):204-211. Pubmedid: 15212320.
  • Kumar N, Allen K, Riccardi D, Bercu B, Cantor A, Minton S, Balducci L, Jacobsen P. Fatigue, weight gain, lethargy and amenorrhea in breast cancer patients on chemotherapy: is subclinical hypothyroidism the culprit?. Breast Cancer Res Treat. 2004 Jan;83(2):149-159. Pubmedid: 14997046.
  • Kazi A, Wang Z, Kumar N, Falsetti S, Chan T, Dou Q. Structure-activity relationships of synthetic analogs of (-)-epigallocatechin-3-gallate as proteasome inhibitors. Anticancer Res. 2004;24(2B):943-954. Pubmedid: 15161048.
  • Kumar N, Dalton K. Eicosapentaenoic acid: promising nutritional supplement in the treatment of cancer cachexia in elderly patients. J Evidence-Based Integrative Medicine. 2004;1(3):189-194. Pubmedid: noPMID.
  • Kazi A, Daniel KG, Smith DM, Kumar NB, Dou QP. Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochem Pharmacol. 2003 Sep;66(6):965-976. Pubmedid: 12963483.
  • Kazi A, Urbizu D, Kuhn D, Acebo A, Jackson E, Greenfelder G, Kumar N, Dou Q. A natural musaceas plant extract inhibits proteasome activity and induces apoptosis selectively in human tumor and transformed, but not normal and non-transformed, cells. Int J Mol Med. 2003;12(6):879-887. Pubmedid: 14612961.
  • Kumar NB, Cantor A, Allen K, Riccardi D, Cox CE. The specific role of isoflavones on estrogen metabolism in premenopausal women. Cancer. 2002 Feb;94(4):1166-1174. Pubmedid: 11920488. Pmcid: PMC2377415.
  • Burns P, Kumar N. Alternative and complementary nutritional therapies in cancer prevention and treatment: implications in clinical practice. Nutrition. 2001;17(3):274-275. Pubmedid: 11312079.
  • Kumar N, Cantor A, Allen K, Cox C. Android obesity at diagnosis and breast carcinoma survival: Evaluation of the effects of anthropometric variables at diagnosis, including body composition and body fat distribution and weight gain during life span, and survival from breast carcinoma. Cancer. 2000;88(12):2751-2757. Pubmedid: 10870057.
  • Kumar N, Besterman-Dahan K. Nutrients in the chemoprevention of prostate cancer: current and future prospects. Cancer Control. 1999 Nov;6(6):580-586. Pubmedid: 10756389.
  • Kumar N, Allen K, Cantor A, Cox C, Greenberg H, Shah S, Lyman G. Weight gain associated with adjuvant tamoxifen therapy in stage I and II breast cancer: fact or artifact?. Breast Cancer Res Treat. 1997 Jun;44(2):135-143. Pubmedid: 9232272.
  • Kumar N, Lyman G, Allan K, Cox C, Shapira D. Progressive weight gain in women and breast cancer risk: opportunity for breast cancer prevention. Cancer Detect Prev. 1996;20:510-510.
  • Kumar N, Lyman G, Allen K, Cox C, Schapira D. Timing of weight gain and breast cancer risk. Cancer. 1995;76(2):243-249. Pubmedid: 8625099.
  • Schapira DV, Clark RA, Wolff PA, Jarrett AR, Kumar NB, Aziz NM. Visceral obesity and breast cancer risk. Cancer. 1994 Jul;74(2):632-639. Pubmedid: 8033042.
  • Schapira D, Wolff P, Kumar N, Anderson J, Aziz N, Lyman G, Swanson M. The effect of weight loss on estimated breast cancer risk and sex hormone levels. Oncol Rep. 1994;1:613-617.
  • Schapira D, Clark R, Wolff P, Jarrett A, Kumar N. Visceral obesity and breast cancer risk. Cancer. 1994;74(2):632-639.
  • Schapira DV, Pamies RJ, Kumar NB, Herold AH, Van Durme DJ, Woodward LJ, Roetzheim RG. Cancer screening. Knowledge, recommendations, and practices of physicians. Cancer. 1993 Feb;71(3):839-843. Pubmedid: 8431866.
  • Schapira D, Kumar N, Lyman G. Body fat distribution and breast cancer risk within families. Cancer. 1993;70:2764-2768.
  • Schapira D, Pamies R, Kumar N, Herold A, VanDurme D, Woodward L, Roetzheim R. Cancer screening -knowledge, recommendations and practices of physicians. Cancer. 1993;71(3):839-843.
  • Kumar N, Bostow D, Schapira D, Kritch K. Efficacy of interactive, automated programmed instruction in nutrition education for cancer prevention. J Cancer Educ. 1993;8(3):203-211.
  • Schapira D, Kumar N, Lyman G. Variation in body fat distribution and breast cancer risk in the families of patients with breast cancer and control families. Cancer. 1993;71(9):2764-2768.
  • Schapira DV, Kumar NB, Clark RA, Yag C. Mammography screening credit card and compliance. Cancer. 1992 Jul;70(2):509-512. Pubmedid: 1617601.
  • Schapira D, Kumar N, Lyman G, Cavanagh D, Roberts W, LaPolla J. Upper body fat distribution and endometrial cancer risk. Jama South American Edition. 1992;266:82-86.
  • Schapira D, Kumar N, Clark R, Yag C. Mammography screening credit card and compliance. Cancer. 1992;70:509-512.
  • Schapira DV, Kumar NB, Lyman GH, Cavanagh D, Roberts WS, LaPolla J. Upper-body fat distribution and endometrial cancer risk. Jama. 1991 Oct;266(13):1808-1811. Pubmedid: 1890709.
  • Schapira DV, Kumar NB, Lyman GH, Baile WF. The effect of duration of intervention and locus of control on dietary change. Am J Prev Med. 1991 Nov;7(6):341-347. Pubmedid: 1790041.
  • Schapira DV, Kumar NB, Lyman GH. Obesity, body fat distribution, and sex hormones in breast cancer patients. Cancer. 1991 Apr;67(8):2215-2218. Pubmedid: 2004343.
  • Schapira DV, Kumar NB, Lyman GH. Serum cholesterol reduction with tamoxifen. Breast Cancer Res Treat. 1990 Nov;17(1):3-7. Pubmedid: 2095926.
  • Schapira DV, Kumar NB. Disease prevention. A link missing. Arch Intern Med. 1989 Jun;149(6):1253-1254. Pubmedid: 2730245.
  • Kumar NB, Hopkins K, Allen K, Riccardi D, Besterman-Dahan K, Moyers S. Use of complementary/integrative nutritional therapies during cancer treatment: implications in clinical practice. Cancer Control. 9(3):236-243. Pubmedid: 12060821.